An open label trial in healthy volunteers designed to confirm neuroanatomical expression of TARP 8 and establish the relationship between PK and brain target RO with RAP-219
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs RAP 219 (Primary)
- Indications Bipolar disorders; Neuropathic pain; Partial epilepsies
- Focus Adverse reactions; Pharmacokinetics
- Acronyms The PET trial
- 15 Jan 2025 New trial record
- 09 Jan 2025 Results presented in the Rapport Therapeutics Media Release.
- 09 Jan 2025 Status changed from recruiting to completed.